Patient-Reported Outcomes from a 1-Year Real-World Head-to-HeadComparison of OnabotulinumtoxinA and Topiramate for Headache Prevention inAdults With Chronic Migraine

摘要

Chronic migraine (CM) is associated with impaired health-related quality oflife and substantial socioeconomic burden, but many people with CM areunderdiagnosed and do not receive appropriate preventive treatment.OnabotulinumtoxinA and topiramate have demonstratedefficacy (treatment benefit under ideal conditions) forthe prevention of headaches in people with CM in clinical trials, butreal-world studies suggest markedly different clinicaleffectiveness (treatment benefit based on a blend ofefficacy and tolerability). This study sought to evaluate patient-reportedoutcomes (PROs) of onabotulinumtoxinA versus topiramate immediate releasefor people with CM.